Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

Project collaboration partner will have option to negotiate licensing and supply agreement ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

Those of you who use classic Outlook may have noticed the program acting more temperamental than usual. There's a reason for ...

Microsoft has finally fixed a problem that causes Outlook to unexpectedly crash on Windows Server 2016 devices. The Current ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...

In our Energy Outlook, we detail our forecasts on fossil fuel, renewables, carbon capture and storage, hydrogen, and utilities ...